POST EVENT REPORT - American DDF Summit · R&D 38.9% “The DDF event is getting better with every...
16
28 – 29 August 2017 | Boston POST EVENT REPORT ddfsummit.com
Transcript of POST EVENT REPORT - American DDF Summit · R&D 38.9% “The DDF event is getting better with every...
28 – 29 August 2017 | Boston
POST EVENTREPORT
ddfsummit.com
IntroIn 2017 the American DDF Summit moved to the East Coast for the first time. Having built up an audience and a community in California over 6 years, the time was right to engage the Eastern biotech hubs.
The DDF Summit series is built around the key relationship between academia and industry. By inviting academic speakers with strong ties to pharmaceutical and biotech companies, the summit is positioned at the cutting edge of modern drug development.
The agenda is at the same time highly scientific and pertinent to real pharmaceutical products, providing both real commercial value and intellectual insight to senior drug developers across America.
Read on to discover more about who was there, what they learned and what they thought.
Statistics
REGISTERED ATTENDEES
SAID THE SUMMIT MET, EXCEEDED OR GREATLY EXCEEDED THEIR EXPECTATIONS
LEARNED SOMETHING NEW AND USEFUL TO THEIR WORK
MET SOMEONE WHO CAN HELP WITH THEIR CURRENT CHALLENGES
WOULD ATTEND AGAIN WOULD RECOMMEND THE SUMMIT TO A COLLEAGUE
What Did the Attendees Think?“Very informative. I made good connections with other formulation Scientists.”Xu SjostromSenior Research Scientist, Noven Pharmaceuticals
“Very good; the quality of presentations was very high”Martin FolgerHead of Global CMC Development Pharmaceuticals, Boehringer Ingelheim Vetmedica
“I have enjoyed the conference, gained an updated overview of the field and learned technical approaches and strategies that are helpful for solving challenges in my projects”Yi AoAssociate Director, Pharma Dev, Zosano Pharma
“Great conference with an impressive program and faculty”Joel RichardSVP Peptides Development, Ipsen
“Enjoyed it, two-day meeting is just perfect to cover the material. I liked the set up with small molecule/biologics sessions at the same time.”Tarek ZeidanPrincipal Scientist, Alkermes
“Focussed and at the same time diverse, with many different presentations and topics”Beata Sweryda-KrawiecResearch Leader, Tarveda Therapeutics
“Good local meeting with relevant presentations and vendors”Mark StrohmeierFellow I, Vertex Pharma
“Excellent attendee list, great networking”Eric BlomgrenBusiness Development, Capsugel
“I enjoyed my experience, learned a lot, and found all the talks interesting”Tamera GoodingPrincipal Research Associate, Sanofi
“Very good organization. The schedule is easy to follow. It is informative.”Changai XuSAS, Jounce Therapeutics
“It is a very good
meeting”
Jimmy Chen
Shionogi
“Good, focused
subject area, right mix
of audience”
Michael Rashed
USP “Great opportunity
for networking with
colleagues facing the
same challenges”
Bernardo Perez-Ramirez
Sanofi
Explore the ContentClick on any presentation to see the full set of slides.Click on any presentation to see the full set of slides.
Improving Oral Bioavailability by Solid Dispersions: An OSPHENA® (Ospemifene) Case Study
Zhengming (Jimmy) ChenSenior Director , Pharmaceutical Sciences | Shionogi
Non-Invasive Delivery Routes for Peptides: Focus on Successful Oral Technologies Progressing in the Clinic
and Future Challenges Joel Richard
SVP, Peptides Development | Ipsen
Molecular Dynamics Simulations of Amorphous SystemsBradley D. Anderson
Professor, Department of Pharmaceutical Sciences | University of Kentucky
Unleash Automated Buffer ExchangeJoe Barco
Senior Director, Marketing | Unchained Labs
Molar Mass, Size, Charge and Conformation: Light Scattering Tools for Characterizing and Formulating
Macromolecules and NanoparticlesJohn Champagne
Senior Applications Scientist | Wyatt Technology Corporation
Explore the ContentClick on any presentation to see the full set of slides.Click on any presentation to see the full set of slides.
Beyond Aseptic Processing Mason Schwartz
Director of R&D | REVOX Sterilization Solutions
High Throughput Screening of a Monoclonal Antibody: Practical Considerations
Myrna MonckDirector, Biopharm Technologies | GSK
Thermal Stabilization of Freeze Sensitive Adjuvanted Vaccine Formulations through Spray Drying
Lillian LiScientist | Sanofi Pasteur
Prediction of Commercial Scale Thaw Time from Lab Scale By CFD Modeling
Mita MaityResearch Scientist, Drug product Science and Technology | BMS
Analyzing the Potential Root Causes of Variability of Pharmacokinetics in Preclinical Species to Inform
Derisking Strategies in Discovery and Early DevelopmentPierre Daublain
Principal Scientist | MSD
Explore the ContentClick on any presentation to see the full set of slides.Click on any presentation to see the full set of slides.
Practical Considerations in Developing High Concentration Antibody Formulations
Qingyan HuScientist | Regeneron Pharmaceuticals
Recent Advances in siRNA Delivery for Resistant Cancers
Vladimir Torchilin, Ph.D., D.Sc.University Distinguished Professor | Center for Pharmaceutical
Biotechnology and Nanomedicine Northeastern University
A Two-Phase Dissolution-Partition Test for Characterization of BCS II/IV Drugs and Formulations
Ping GaoResearch Fellow | AbbVie
Is it Crystal Clear? Stability Prediction for Amorphous PharmaceuticalsSunny Bhardwaj
Senior Scientist | MSD
Who Was There?
The summit attracts senior pharmaceutical development and formulation scientists from across pharma big and small. Companies in attendance in 2017 included:
AbbVie
Alkermes
Bayer
Boehringer Ingelheim
Dimension Therapeutics
Ferring
Acorda
Ascil
Biogen
Celgene
Eli Lilly
Acceleron
Amgen
Berg Health
BMS
Eisai
Aegerion
Axcella
BioPharmX
Decibel TherapeuticsCapsugel
Enanta
ACORDATHERAPEUTICS
Recreated Logo
Found from websiterecreate PMS
Now a Lonza Company
Who Was There? Continued
“Very applicable to my technical and business interests”Bruce ArtmanVP, R&D, Vizuri Health Sciences
GSK ImmunoGen
Jounce Therapeutics
Liquida Technologies
Novartis
Sandoz
Ironwood Pharma
LakePharma
MedImmuneLuye Pharma
Pfizer
Ipsen
Intelgenx
Kura Oncology
Pearl Therapeutics
Jazz Pharma
Lexicon Pharmaceuticals
Merck
Regeneron
Original
Find from PDF recreate PMS
Genzyme
Who Was There? Continued
Tesaro
Takeda
Zafgen
Shionogi
Shire
Theravance Biopharma
Saptalis
Teva
Teikoku Seiyaku
Zosano Pharma
Sanofi
Sunovion Pharma
Xenetic Biosciences
Shepherd Therapeutics
“The speakers were experts in their field and in the talks I attended, I did learn a lot of the various technologies, challenges and solutions proposed by the experts.”Anthony BoeyHead, Formulations, CDRD
Who Was There? Continued
By company type:
Pharmaceuticals: 68.8%Delivery / Formulation Services: 28.9%University: 2.3%
By seniority:n Director 20.5%n Principal Scientist 18.8%n Senior Scientist / Engineer 17.0%n Scientist 12.5%n Head 11.6%n VP 11.6%n Specialist / Expert 5.4%n C-Level 2.7%
By job function:
R&D 38.9%
“The DDF event is getting better with every year... It is really worth coming.”Monika Brink, Senior Manager, Outsourcing R&D CMC, Boehringer Ingelheim Vetmedica
Formulation Development 20.0%
Pharmaceutical Development 20.0%
Process Development / Manufacturing 6.3%
Analytical Development 5.3%CMC 3.2%Drug Delivery 3.2%Other 3.2%
By investment priorities:Priority Investment Area - % of delegates*
*Of the 44 delegates taking part in iSolve meetings
“Well done - well organized with the two tracks (Bio vs. Sm. Molecule) - nice venue and friendly atmosphere”Becky Nissley Biopharmaceutics - Preclinical Development Scientist, Merck Research Labs
Formulated Design Technologies 84.1%
Delivery Challenges 81.8%
Delivery Methods & Devices 77.3%
Delivery Technologies 72.7%Targeted Delivery 70.5%
Strategy & Planning 63.6%
Manufacturing / Scale-up 61.4%Modified / Controlled Release 59.1%
Who Was There? Continued
Commercial Partners
If you’d like to be a Commercial Partner in 2018 then please contact:
Alexandra Krcho [email protected]
Dow Pharma Solutionswww.dowpharmasolutions.com
Foster Delivery Sciencewww.deliveryscience.com
Nanologicawww.nanologica.com
Owen Mumfordwww.owenmumford.com
Precision Nanosystemswww.precisionnanosystems.com
Pfanstiehlwww.pfanstiehl.com
Patheonwww.patheon.com
Revox Sterilization Solutionswww.revoxsterilization.com
Redshift BioAnalyticswww.redshiftbio.com
CBSETwww.cbset.org
Captisolwww.captisol.com
Cure Pharmaceuticalswww.curepharmaceutical.com
Bachemwww.bachem.com
Capsugelwww.capsugel.com
CASwww.cas.org
iCeutica Operationswww.iceutica.com
Leon Nanodrugswww.leon-nanodrugs.com
MW Industrieswww.mw-ind.com
KBI Biopharmawww.kbibiopharma.com
Quotient Clinicalwww.quotientclinical.com
Quay Pharmawww.quaypharma.com
Unchained Labswww.unchainedlabs.com
Wyatt Technologywww.wyatt.com
Thank you to our Commercial Partners, without whom the summit couldn’t exist.
Now a Lonza Company
BioAnalytics
See the Highlights
Video
Photos
Click the links below to see the highlights video and some photos from the summit.
”If you offer services or solutions to drug developing companies and you have commercial responsibilities, then you can only attend as a Commercial Partner.
Contact Alexandra Krcho ([email protected], +44 (0) 20 3874 9205) to explore the possibilities.
2.
”
September 10 – 11, 2018 | San Francisco ddsummit.com
Next year the American DDF Summit will continue its journey, moving back to West Coast. A hotbed for pharmaceutical development activity, the area is sure to uncover some of the most exciting work being done in the field.
This is an opportunity to re-engage with the leading drug developers on the West Coast, meet younger companies with recent investment and educate the market on your offering.
Looking ahead to 2018
Looking across the Atlantic…
March 12 – 14 2018 | Berlinwww.ddfevent.com
“Great event, high quality participants and talks.”
Michael Baumann, Pharma Field Marketing Manager EMEA, DOW Chemical
“A very good get-together for Drug delivery stakeholders.”
Ann Gidner, Business Development & Sales Director, Albumedix
The flagship DDF Summit returns to Berlin in 2018
200+ pharmaceutical development leaders. 60+ expert speakers . 30+ solution providers
After a hugely successful two years at the Maritim proArte in Berlin we return in 2018. Next year we’ll take even more space to
accommodate further growth of the summit.
This means a 4th room for an extra agenda stream focused on Device Development and Delivery.
There are discounts available for American delegates. Contact us at [email protected] for more information.
